English News in Levels

FDA Greenlights Veppanu, the First PROTAC Cancer Drug, for ESR1-Mutated Breast Cancer

On 1 May 2026 the U.S. Food and Drug Administration approved Pfizer and Arvinas's vepdegestrant, branded Veppanu, for adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer who have had at least one prior endocrine therapy. It is the first PROteolysis TArgeting Chimera, or PROTAC, ever to clear the FDA — a drug that destroys disease-driving proteins rather than merely blocking them.